Antidepressants differentially influence the transcriptional activity of the glucocorticoid receptor in vitro

Neuroendocrinology

Volumn 78, Issue 1, 2003, Pages 12-22

  Herr, Alexandra S ^a   Tsolakidou, Amalia F ^a   Yassouridis, Alexander ^a   Holsboer, Florian ^a   Rein, Theo ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Adrenal steroid receptors; Adrenal steroids; Antidepressants; Depression; Glucocorticoid receptors; Molecular neuroendocrinology

Indexed keywords

ALPHA TOCOPHEROL; ANTIDEPRESSANT AGENT; ANTIOXIDANT; CORTICOSTEROID; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; PEROXIDE; STEROID;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL LINE; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIOXIDANTS; CELL LINE; HIPPOCAMPUS; MICE; MONOAMINE OXIDASE INHIBITORS; OXIDATIVE STRESS; P-GLYCOPROTEIN; RECEPTORS, GLUCOCORTICOID; SEROTONIN UPTAKE INHIBITORS; STEROIDS; TRANSCRIPTION, GENETIC;

EID: 0042665872     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000071701     Document Type: Article

References (65)

1. Holsboer F: The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000;23:477-501.
2. Manji HK, Drevets WC, Charney DS: The cellular neurobiology of depression. Nat Med 2001;7:541-547.
3. Rubin RT, Poland RE, Lesser IM, Winston RA, Blodgett AL: Neuroendocrine aspects of primary endogenous depression. I. Cortisol secretory dynamics in patients and matched controls. Arch Gen Psychiatry 1987;44:328-336.
4. Rubin RT, Phillips JJ, Sadow TF, McCracken JT: Adrenal gland volume in major depression. Increase during the depressive episode and decrease with successful treatment. Arch Gen Psychiatry 1995;52:213-218.
5. Nemeroff CB, Widerlov E, Bissette G, Walleus H, Karlsson I, Eklund K, Kilts CD, Loosen PT, Vale W: Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984;226:1342-1344.
6. Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M: Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 1988;45:577-579.
7. Raadsheer FC, Hoogendijk WJ, Stam FC, Tilders FJ, Swaab DF: Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 1994;60:436-444.
8. Strickland PL, Deakin JF, Percival C, Dixon J, Gater RA, Goldberg DP: Bio-social origins of depression in the community. Interactions between social adversity, cortisol and serotonin neurotransmission. Br J Psychiatry 2002;180:168-173.
9. Cowen PJ: Cortisol, serotonin and depression: All stressed out? Br J Psychiatry 2002;180:99-100.
10. Zhou DF, Shen YC, Shu LN, Lo HC: Dexamethasone suppression test and urinary MHPG X SO4 determination in depressive disorders. Biol Psychiatry 1987;22:883-891.
11. Heuser I, Yassouridis A, Holsboer F: The combined dexamethasone/CRH test: A refined laboratory test for psychiatric disorders. J Psychiatr Res 1994;28:341-356.
12. Rybakowski JK, Twardowska K: The dexamethasone/corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness. J Psychiatr Res 1999;33:363-370.
13. von Bardeleben U, Holsboer F: Effect of age on the cortisol response to human corticotropin-releasing hormone in depressed patients pre-treated with dexamethasone. Biol Psychiatry 1991;29:1042-1050.
14. Rupprecht R, Wodarz N, Kornhuber J, Wild K, Schmitz B, Braner HU, Muller OA, Riederer P, Beckmann H: In vivo and in vitro effects of glucocorticoids on lymphocyte proliferation in depression. Eur Arch Psychiatry Clin Neurosci 1991;241:35-40.
15. Bauer ME, Papadopoulos A, Poon L, Perks P, Lightman SL, Checkley S, Shanks N: Altered glucocorticoid immunoregulation in treatment resistant depression. Psychoneuroendocrinology 2003;28:49-65.
16. Holsboer F, Liebl R, Hofschuster E: Repeated dexamethasone suppression test during depressive illness. Normalisation of test result compared with clinical improvement. J Affect Disord 1982;4:93-101.
17. Greden JF, Gardner R, King D, Grunhaus L, Carroll BJ, Kronfol Z: Dexamethasone suppression tests in antidepressant treatment of melancholia. The process of normalization and test-retest reproducibility. Arch Gen Psychiatry 1983;40:493-500.
18. Holsboer F, Gerken A, Stalla GK, Muller OA: ACTH, cortisol, and corticosterone output after ovine corticotropin-releasing factor challenge during depression and after recovery. Biol Psychiatry 1985;20:276-286.
19. Pfeiffer A, Barden N: Glucocorticoid receptor gene expression in rat pituitary gland intermediate lobe following ovariectomy. Mol Cell Endocrinol 1988;55:115-120.
20. Przegalinski E, Budziszewska B: The effect of long-term treatment with antidepressant drugs on the hippocampal mineralocorticoid and glucocorticoid receptors in rats. Neurosci Lett 1993;161:215-218.
21. Przegalinski E, Budziszewska B, Siwanowicz J, Jaworska L: The effect of repeated combined treatment with nifedipine and antidepressant drugs or electroconvulsive shock on the hippocampal corticosteroid receptors in rats. Neuropharmacology 1993;32:1397-1400.
22. Seckl JR, Fink G: Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology 1992;55:621-626.
23. Reul JM, Stec I, Soder M, Holsboer F: Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 1993;133:312-320.
24. Shelton RC: Intracellular Mechanisms of antidepressant drug action. Harv Rev Psychiatry 2000;8:161-174.
25. Brady LS, Whitfield HJJ, Fox RJ, Gold PW, Herkenham M: Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J Clin Invest 1991;87:831-837.
26. Rossby SP, Nalepa I, Huang M, Perrin C, Burt AM, Schmidt DE, Gillespie DD, Sulser F: Norepinephrine-independent regulation of GRII mRNA in vivo by a tricyclic antidepressant. Brain Res 1995;687:79-82.
27. Montkowski A, Barden N, Wotjak C, Stec I, Ganster J, Meaney M, Engelmann M, Reul JM, Landgraf R, Holsboer F: Long-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function. J Neuroendocrinol 1995;7:841-845.
28. Pepin MC, Pothier F, Barden N: Impaired type II glucocorticoid-receptor function in mice bearing antisense RNA transgene. Nature 1992;355:725-728.
29. Brady LS, Gold PW, Herkenham M, Lynn AB, Whitfield HJJ: The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res 1992;572:117-125.
30. Budziszewska B, Siwanowicz J, Przegalinski E: The effect of chronic treatment with antidepressant drugs on the corticosteroid receptor levels in the rat hippocampus. Pol J Pharmacol 1994;46:147-152.
31. Pariante CM, Miller AH: Glucocorticoid receptors in major depression: Relevance to pathophysiology and treatment. Biol Psychiatry 2001;49:391-404.
32. Pariante CM, Pearce BD, Pisell TL, Owens MJ, Miller AH: Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine. Mol Pharmacol 1997;52:571-581.
33. Pepin MC, Govindan MV, Barden N: Increased glucocorticoid receptor gene promoter activity after antidepressant treatment. Mol Pharmacol 1992;41:1016-1022.
34. Budziszewska B, Jaworska-Feil L, Kajta M, Lason W: Antidepressant drugs inhibit glucocorticoid receptor-mediated gene transcription - a possible mechanism. Br J Pharmacol 2000; 130:1385-1393.
35. Glotzbach RK, Preskorn SH: Brain concentrations of tricyclic antidepressants: Single-dose kinetics and relationship to plasma concentrations in chronically dosed rats. Psychopharmacology (Berl) 1982;78:25-27.
36. Hrdina PD, Dubas TC: Brain distribution and kinetics of desipramine in the rat. Can J Physiol Pharmacol 1981;59:163-167.
37. Miyake K, Fukuchi H, Kitaura T, Kimura M, Sarai K, Nakahara T: Pharmacokinetics of amitriptyline and its demethylated metabolite in serum and specific brain regions of rats after acute and chronic administration of amitriptyline. J Pharm Sci 1990;79:288-291.
38. Post A, Crochemore C, Uhr M, Holsboer F, Behl C: Differential induction of NF-kappaB activity and neural cell death by antidepressants in vitro. Eur J Neurosci 2000;12:4331-4337.
39. Makino Y, Yoshikawa N, Okamoto K, Hirota K, Yodoi J, Makino I, Tanaka H: Direct association with thioredoxin allows redox regulation of glucocorticoid receptor function. J Biol Chem 1999;274:3182-3188.
40. Bodwell JE, Holbrook NJ, Munck A: Evidence for distinct sulfhydryl groups associated with steroid- and DNA-binding domains of rat thymus glucocorticoid receptors. Biochemistry 1984;23:4237-4242.
41. Makino Y, Okamoto K, Yoshikawa N, Aoshima M, Hirota K, Yodoi J, Umesono K, Makino I, Tanaka H: Thioredoxin: a redox-regulating cellular cofactor for glucocorticoid hormone action. Cross talk between endocrine control of stress response and cellular antioxidant defense system. J Clin Invest 1996;98:2469-2477.
42. Hutchison KA, Matic G, Meshinchi S, Bresnick EH, Pratt WB: Redox manipulation of DNA binding activity and BuGR epitope reactivity of the glucocorticoid receptor. J Biol Chem 1991;266:10505-10509.
43. Chakraborti PK, Garabedian MJ, Yamamoto KR, Simons SS: Role of cysteines 640, 656, and 661 in steroid binding to rat glucocorticoid receptors. J Biol Chem 1992;267:11366-11373.
44. Morimoto BH, Koshland DEJ: Induction and expression of long- and short-term neurosecretory potentiation in a neural cell line. Neuron 1990;5:875-880.
45. Herr A, Wochnik GM, Rosenhagen MC, Holsboer F, Rein T: Rifampicin is not an activator of the glucocorticoid receptor. Mol Pharmacol 2000;57:732-737.
46. Hollenberg SM, Evans RM: Multiple and cooperative trans-activation domains of the human glucocorticoid receptor. Cell 1988;55:899-906.
47. Behl C, Davis JB, Lesley R, Schubert D: Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 1994;77:817-827.
48. Raber J: Detrimental effects of chronic hypothalamic-pituitary-adrenal axis activation. From obesity to memory deficits. Mol Neurobiol 1998;18:1-22.
49. Born J, Fehm HL: Hypothalamus-pituitary-adrenal activity during human sleep: a coordinating role for the limbic hippocampal system. Exp Clin Endocrinol Diabetes 1998;106:153-163.
50. De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M: Brain corticosteroid receptor balance in health and disease. Endocr Rev 1998;19:269-301.
51. Pariante CM, Makoff A, Lovestone S, Feroli S, Heyden A, Miller AH, Kerwin RW: Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. Br J Pharmacol 2001;134:1335-1343.
52. Okugawa G, Omori K, Suzukawa J, Fujiseki Y, Kinoshita T, Inagaki C: Long-term treatment with antidepressants increases glucocorticoid receptor binding and gene expression in cultured rat hippocampal neurones. J Neuroendocrinol 1999;11:887-895.
53. Reul JM, Labeur MS, Grigoriadis DE, De Souza EB, Holsboer F: Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology 1994;60:509-519.
54. Steckler T, Rammes G, Sauvage M, van Gaalen MM, Weis C, Zieglgansberger W, Holsboer F: Effects of the monoamine oxidase A inhibitor moclobemide on hippocampal plasticity in GR-impaired transgenic mice. J Psychiatr Res 2001;35:29-42.
55. Bjartmar L, Johansson IM, Marcusson J, Ross SB, Seckl JR, Olsson T: Selective effects on NGFI-A, MR, GR and NGFI-B hippocampal mRNA expression after chronic treatment with different subclasses of antidepressants in the rat. Psychopharmacology (Berl) 2000;151:7-12.
56. Sillaber I, Montkowski A, Landgraf R, Barden N, Holsboer F, Spanagel R: Enhanced morphine-induced behavioural effects and dopamine release in the nucleus accumbens in a transgenic mouse model of impaired glucocorticoid (type II) receptor function: influence of long-term treatment with the antidepressant moclobemide. Neuroscience 1998;85:415-425.
57. Then Bergh F, Kumpfel T, Grasser A, Rupprecht R, Holsboer F, Trenkwalder C: Combined treatment with corticosteroids and moclobemide favors normalization of hypothalamo-pituitary-adrenal axis dysregulation in relapsing-remitting multiple sclerosis: a randomized, double blind trial. J Clin Endocrinol Metab 2001;86:1610-1615.
58. Alpsoy E, Ozcan E, Cetin L, Ozgur O, Er H, Yilmaz E, Karaman T: Is the efficacy of topical corticosteroid therapy for psoriasis vulgaris enhanced by concurrent moclobemide therapy? A double-blind, placebo-controlled study. J Am Acad Dermatol 1998;38:197-200.
59. Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ, Akil H: Mineralocorticoid receptor function in major depression. Arch Gen Psychiatry 2003;60:24-28.
60. Schüle C, Baghai T, Goy J, Bidlingmaier M, Strasburger C, Laakmann G: The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects. Psychopharmacology (Berl) 2002;163:95-101.
61. Sapolsky RM, Krey LC, McEwen BS: The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis. Endocr Rev 1986;7:284-301.
62. Brown ES, Rush AJ, McEwen BS: Hippocampal remodeling and damage by corticosteroids: implications for mood disorders. Neuropsychopharmacology 1999;21:474-484.
63. Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C, Schatzberg AF: An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 2002;52:386-392.
64. Gold P, Drevets W, Charney D: New insights into the role of cortisol and the glucocorticoid receptor in severe depression. Biol Psychiatry 2002;52:381.
65. Uhr M, Holsboer F, Muller MB: Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins. J Neuroendocrinol 2002;14:753-759.